ES2121461T3 - Utilizacion de un antagonista de cgrp para tratar el eritema cutaneo de origen neurogenico y composicion asi obtenida. - Google Patents

Utilizacion de un antagonista de cgrp para tratar el eritema cutaneo de origen neurogenico y composicion asi obtenida.

Info

Publication number
ES2121461T3
ES2121461T3 ES96400457T ES96400457T ES2121461T3 ES 2121461 T3 ES2121461 T3 ES 2121461T3 ES 96400457 T ES96400457 T ES 96400457T ES 96400457 T ES96400457 T ES 96400457T ES 2121461 T3 ES2121461 T3 ES 2121461T3
Authority
ES
Spain
Prior art keywords
eritema
composition
cgrp antagonist
neurogenic origin
treat cutaneous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96400457T
Other languages
English (en)
Other versions
ES2121461T5 (es
Inventor
Lacharriere Olivier De
Lionel Breton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9477498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2121461(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by LOreal SA filed Critical LOreal SA
Publication of ES2121461T3 publication Critical patent/ES2121461T3/es
Application granted granted Critical
Publication of ES2121461T5 publication Critical patent/ES2121461T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA INVENCION SE REFIERE A LA UTILIZACION DE UN ANTAGONISTA DE CGRP EN UNA COMPOSICION COSMETICA FARMACEUTICA O DERMATOLOGICA, PARTICULARMENTE DE APLICACION TOPICA, PARA TRATAR LAS MANCHAS ROJAS CUTANEAS DE ORIGEN NEUROGENO, Y PARTICULARMENTE EL ACNE ROSACEA Y EL ERITEMA PUDICO.
ES96400457T 1995-03-28 1996-03-04 Utilizacion de un antagonista de cgrp para tratar el eritema cutaneo de origen neurogenico y composicion asi obtenida. Expired - Lifetime ES2121461T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9503628A FR2732221B1 (fr) 1995-03-28 1995-03-28 Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
FR9503628 1995-03-28

Publications (2)

Publication Number Publication Date
ES2121461T3 true ES2121461T3 (es) 1998-11-16
ES2121461T5 ES2121461T5 (es) 2005-05-01

Family

ID=9477498

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96400457T Expired - Lifetime ES2121461T5 (es) 1995-03-28 1996-03-04 Utilizacion de un antagonista de cgrp para tratar el eritema cutaneo de origen neurogenico y composicion asi obtenida.

Country Status (15)

Country Link
US (2) US5932215A (es)
EP (1) EP0734729B2 (es)
JP (1) JPH08268874A (es)
AR (1) AR002974A1 (es)
AT (1) ATE168011T1 (es)
BR (1) BR9601478A (es)
CA (1) CA2172777C (es)
DE (1) DE69600399T3 (es)
DK (1) DK0734729T4 (es)
ES (1) ES2121461T5 (es)
FR (1) FR2732221B1 (es)
HU (1) HUP9600765A3 (es)
MX (1) MX9601150A (es)
PL (1) PL313515A1 (es)
RU (1) RU2152798C1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2728793A1 (fr) * 1994-12-28 1996-07-05 Oreal Utilisation d'un antagoniste d'histamine, d'un antagoniste d'interleukine 1 et/ou d'un antagoniste de tnf-alpha dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
US6416760B2 (en) * 1995-01-26 2002-07-09 Societe L'oreal Therapeutic/cosmetic compositions comprising CGRP antagonists for treating sensitive human skin
FR2768621B1 (fr) * 1997-09-22 2000-04-07 Oreal Utilisation d'un extrait d'au moins un vegetal de la famille des rosacees
US5972993A (en) * 1998-03-20 1999-10-26 Avon Products, Inc. Composition and method for treating rosacea and sensitive skin with free radical scavengers
CA2301336A1 (en) * 2000-03-17 2001-09-17 Michael T. Kelly Topical treatment of rosacea
US7078048B2 (en) * 2001-05-09 2006-07-18 The Regents Of The University Of Michigan Method and compositions for treating rosacea
US6680062B2 (en) 2001-10-05 2004-01-20 Color Access, Inc. Anti-irritating rosacea treatment
US6723755B2 (en) 2002-06-12 2004-04-20 Piotr Chomczynski Method of treating rosacea
CN1674919A (zh) 2002-08-12 2005-09-28 比克尔·斯韦恩森 Cgrp拮抗剂化合物在治疗牛皮癣中的应用
US8410102B2 (en) * 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7812057B2 (en) * 2004-08-25 2010-10-12 Molecular Research Center, Inc. Cosmetic compositions
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
CN101065014A (zh) * 2004-09-23 2007-10-31 亚历山大·米哈洛 通过诱导逆适应调节神经递质系统的方法
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
PL3045182T3 (pl) 2005-11-14 2018-07-31 Teva Pharmaceuticals International Gmbh Przeciwciała antagonistyczne skierowane przeciwko peptydowi związanemu z genem kalcytoniny do leczenie klastrowego bólu głowy
CN107296957A (zh) 2008-03-04 2017-10-27 梯瓦制药国际有限责任公司 治疗慢性疼痛的方法
EP2307001A1 (en) * 2008-06-11 2011-04-13 BioChemics, Inc. Control of blood vessel physiology to treat skin disorders
CA2749941C (en) 2008-09-10 2018-04-24 Biochemics, Inc. Ibuprofen for topical administration
MX349176B (es) 2008-09-22 2017-07-14 Biochemics Inc Suministro transdermico de farmaco empleando un osmolito y un agente vasoactivo.
WO2010065922A2 (en) * 2008-12-04 2010-06-10 Biochemics, Inc. Methods and compositions for tattoo removal
US8263581B2 (en) * 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
CN102740884A (zh) 2009-08-28 2012-10-17 瑞纳神经科学公司 通过施用针对降钙素基因相关肽的拮抗性抗体来治疗内脏痛的方法
CN102985091B (zh) 2010-03-03 2016-11-23 新科蒂斯公司 使用抗微生物肽螯合化合物治疗皮肤疾病和异常的组合物和方法
AU2011231543B2 (en) 2010-03-26 2015-01-15 Galderma Research & Development Improved methods and compositions for safe and effective treatment of erythema
EP2709663B1 (en) 2011-05-20 2019-03-20 AlderBio Holdings LLC Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
MX365813B (es) 2011-05-20 2019-06-14 Alderbio Holdings Llc Uso de anticuerpos anti-cgrp o anti-cgrp o fragmentos de anticuerpo para tratar o prevenir formas crónicas y agudas de diarrea.
ES2715001T3 (es) 2011-05-20 2019-05-31 Alderbio Holdings Llc Composiciones anti-CGRP y uso de las mismas
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
DK3119431T3 (da) 2014-03-21 2024-03-18 Teva Pharmaceuticals Int Gmbh Antagonistantistoffer rettet mod calcitoningen-relateret peptid og fremgangsmåder til anvendelse deraf
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
FR3030521B1 (fr) * 2014-12-23 2019-07-26 Galderma Research & Development Nouveaux composes heterocycliques et leur utilisation en medecine ainsi qu'en cosmetique
WO2017001434A1 (en) * 2015-06-29 2017-01-05 Galderma Research & Development Cgrp receptor antagonist compounds for topical treatment of skin disorders
US20180185360A1 (en) * 2015-06-29 2018-07-05 Galderma Research & Development Cgrp receptor antagonist compounds for topical treatment of skin disorders
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519194D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
CN109952314A (zh) 2016-09-23 2019-06-28 泰瓦制药国际有限公司 治疗难治性偏头痛
US11433119B2 (en) 2016-11-18 2022-09-06 Nepsone Ehf Methods of treating inflammatory skin disorders
AU2020206241A1 (en) 2019-01-08 2021-08-26 H. Lundbeck A/S Acute treatment and rapid treatment of headache using anti-CGRP antibodies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164372A (en) * 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
SE9201425D0 (sv) * 1992-05-06 1992-05-06 Kabi Pharmacia Ab Method and means for preventing constriction of the pupil in the eye
TW263498B (es) * 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
CZ286758B6 (en) * 1994-03-21 2000-06-14 Thomsen John Brown Pharmaceutical preparation in the form of a gel for treating skin diseases
DE69529043T2 (de) * 1994-09-30 2003-05-08 L'oreal S.A., Paris Verwendung von einem Agonisten eines mit einem Chloridkanal assozierten Rezeptors zur Behandlung von Hautfalten
US5445823A (en) * 1994-10-20 1995-08-29 The Procter & Gamble Company Dermatological compositions and method of treatment of skin lesions therewith
FR2728165A1 (fr) * 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
FR2728166A1 (fr) * 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
FR2728265A1 (fr) * 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p dans une composition pharmaceutique
FR2728169A1 (fr) * 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
FR2728793A1 (fr) * 1994-12-28 1996-07-05 Oreal Utilisation d'un antagoniste d'histamine, d'un antagoniste d'interleukine 1 et/ou d'un antagoniste de tnf-alpha dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue

Also Published As

Publication number Publication date
HUP9600765A3 (en) 1998-04-28
FR2732221B1 (fr) 1997-04-25
EP0734729B2 (fr) 2004-09-29
JPH08268874A (ja) 1996-10-15
DE69600399T2 (de) 1998-10-29
FR2732221A1 (fr) 1996-10-04
RU2152798C1 (ru) 2000-07-20
US6509014B1 (en) 2003-01-21
CA2172777A1 (fr) 1996-09-29
EP0734729A1 (fr) 1996-10-02
DE69600399D1 (de) 1998-08-13
DK0734729T3 (da) 1999-04-19
MX9601150A (es) 1997-02-28
EP0734729B1 (fr) 1998-07-08
BR9601478A (pt) 1998-06-02
HU9600765D0 (en) 1996-05-28
HUP9600765A2 (en) 1997-06-30
US5932215A (en) 1999-08-03
AR002974A1 (es) 1998-05-27
DE69600399T3 (de) 2005-07-14
PL313515A1 (en) 1996-09-30
CA2172777C (fr) 2007-07-24
DK0734729T4 (da) 2004-10-25
ES2121461T5 (es) 2005-05-01
ATE168011T1 (de) 1998-07-15

Similar Documents

Publication Publication Date Title
ES2121461T3 (es) Utilizacion de un antagonista de cgrp para tratar el eritema cutaneo de origen neurogenico y composicion asi obtenida.
ES2154388T3 (es) Utilizacion de un antagonista de cgrp en una composicion cosmetica, farmaceutica o dermatologica y composicion obtenida.
AR049829A1 (es) Procedimiento y composiciones utiles para prevenir y/o tratar las pieles sensibles y/o secas
ATE311849T1 (de) Verwendung von kosmetische und pharmazeutische zubereitungen enthaltend 2-decarboxy-2-phosphino prostaglandinderivate
DE69532751D1 (de) Kosmetische, pharmazeutische oder dermatologische Zusammensetzung, sowie die Zusammensetzung Alpha-TNFAntagonisten enthaltend
ES2154503T3 (es) Composicion cosmetica o dermatologica.
ES2157307T3 (es) Composicion topica que contiene un antagonista de sustancia p.
FR2815848B1 (fr) Compostion cosmetque contenant un agent de coloration photochrome et son utilisation pour le maquillage et/ou le soin de la peau et/ou des phaneres
AU2002233288A1 (en) Combined use of Enzyme Inhibitors and Pharmaceutical Preparations thereof for the Treatment and Prophylaxis of Arteriosclerosis, for the Treatment and Prevention of Allergic Reactions of Type I According to the Gell and Coombs Classification, and for the Treatment and Prevention of Dermatological Diseases Associated with FO
ATE370730T1 (de) Pharmazeutische zubereitungen, die chelatbildner/sequestriermittel enthalten und deren dermatologische verwendung
AR004089A1 (es) Utilizacion de un antagonista de substancia p en una composicion topica , como agente antitranspirante.
ES2127613T3 (es) Utilizacion de un antagonista de tnf-alfa para el tratamiento de rojeces cutaneas de origen neurogeno.
ATE345160T1 (de) Topisches produkt mit visuellem indikator
ES2159697T3 (es) Utilizacion de un antagonista de cgrp para tratar los liquenes y los pruritos y composicion obtenida.
BR0203109A (pt) Composição de cuidado com a pele que altera a cor sob secagem
ES2160680T3 (es) Utilizacion de un antagonista de sustancia p en una composicion farmaceutica.
ATE413181T1 (de) Therapeutische topische hautlösung und relevante anwendungsmethoden
ES2124983T5 (es) Utilizacion de un antagonista de substancia p para el tratamiento de las manchas rojas cutaneas de origen neurogeno.
ES2184971T3 (es) Utilizacion de polidimetilsiloxanos de grupos glucosidos como agentes hidratantes en una composicion cosmetica o dermatologica.
BR0318343A (pt) composição tópica para administração transdérmica
ATE256392T1 (de) Verwendung von polyaminosäurederivate als konservierungsmittel
ES2121179T3 (es) Utilizacion de un extracto de simarouba para la atenuacion de las manchas pigmentarias de la piel.
ES2163596T3 (es) Utilizacion de un antagonista de cgrp para el tratamiento de los pruritos y de las disestesias oculares o palpebrales.
BR0108980A (pt) Aplicação e formulação farmacêuticas compreendendo inibidor de reabsorção de norepinefrina
ATE467423T1 (de) Pharmazeutische zubereitungen als hydrogel, die diaminooxidase enthalten

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 734729

Country of ref document: ES